Australian consensus recommendations for the management of increased meningococcal infection risk in adults with neurological diseases treated with complement inhibitors.

Authors

Katherine A Buzzard, Michael Barnett, Heidi Beadnall, Mirasol Forcadela, Lesley-Ann Hall, Victoria G Hall, Todd Hardy, Danny Hsu, Paul Kinsella, Mastura Monif, Sudarshini Ramanathan, Stephen W Reddel, Sean Riminton, Douglas F Johnson

Published in

Internal medicine journal. Aug 16, 2026. Epub Aug 16, 2026.

Abstract

Complement inhibitor therapy carries a risk of serious infections, including meningococcal disease. Here we provide evidence-based recommendations and expert consensus for immunisation and prophylactic treatment of patients receiving, or planning to receive, complement inhibitors for neurological conditions in the Australian setting. The primary aim of these consensus recommendations is to minimise the risk of vaccine-preventable infections and to outline alternative infection-prevention strategies where vaccination is problematic. We address disease-specific risks and propose timing considerations, including a pragmatic approach to clinical implementation.

PMID:
42604968
Bibliographic data and abstract were imported from PubMed on 17 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.